NASDAQ
20.11.24
21:44 Uhr
2,190 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Lexaria Bioscience Corp.: ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study | 170 | ACCESSWIRE | DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65%... ► Artikel lesen | |
| 14.11. | Lexaria startet einzigartige Studie zur Arzneimittelverteilung | 2 | Investing.com Deutsch | ||
| 14.11. | Lexaria Bioscience Corp.: Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study | 124 | ACCESSWIRE | World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... ► Artikel lesen | |
| 13.11. | Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss | 201 | ACCESSWIRE | DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global... ► Artikel lesen | |
| 07.11. | Lexaria Bioscience Corp.: Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments | 234 | ACCESSWIRE | DehydraTECH for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a... ► Artikel lesen | |
| 24.10. | Lexaria meldet vielversprechende Ergebnisse zur Blutzuckerkontrolle in Tierstudie | 4 | Investing.com Deutsch | ||
| 24.10. | Lexaria reports promising blood sugar control in animal study | 2 | Investing.com | ||
| LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 24.10. | Lexaria Bioscience Corp.: Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study | 182 | ACCESSWIRE | DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... ► Artikel lesen | |
| 22.10. | Lexaria vermeldet Fortschritte bei Studie zu Abnehmmittel | 2 | Investing.com Deutsch | ||
| 22.10. | Lexaria Bioscience Corp.: Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study | 167 | ACCESSWIRE | DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all... ► Artikel lesen | |
| 18.10. | Lexaria Bioscience Corp. legt Termin für kombinierte Jahres- und Sonderversammlung fest | 1 | Investing.com Deutsch | ||
| 18.10. | Lexaria Bioscience Corp. sets date for combined annual and special meeting | 1 | Investing.com | ||
| 16.10. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10. | Lexaria Bioscience Corp.: Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 256 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed... ► Artikel lesen | |
| 15.10. | Lexaria Bioscience Corp.: Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 209 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it... ► Artikel lesen | |
| 09.10. | Lexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing | 231 | ACCESSWIRE | DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"... ► Artikel lesen | |
| 08.10. | Lexaria Bioscience Corp.: Lexaria Updates Current GLP-1 Market | 204 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update... ► Artikel lesen | |
| 02.10. | Lexaria Bioscience ernennt Michael Shankman zum neuen CFO | 1 | Investing.com Deutsch | ||
| 02.10. | Lexaria Bioscience appoints new CFO Michael Shankman | 2 | Investing.com | ||
| 02.10. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EMEIS | 5,705 | +1,44 % | emeis: Upturn in Performance Confirmed in Third-Quarter 2024 | Revenue up +8.3%, occupancy rate up +2.6 points
Regulatory News:
emeis (Paris:EMEIS):
Growth in all core activities and in all geographical areas (revenue and occupancy rate)
Solid... ► Artikel lesen | |
| EMPOWER CLINICS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.07.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 30.07.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.07.2024ISIN NameCA29246V2030 EMPOWER... ► Artikel lesen | |
| NANO-X IMAGING | 5,760 | -2,21 % | Nano-X Imaging Ltd reports results for the quarter ended September 30 - Earnings Summary | ||
| BUTTERFLY NETWORK | 3,275 | -1,50 % | BFLY-Aktie erreicht 52-Wochen-Hoch bei 2,95 US-Dollar | ||
| TALKSPACE | 3,245 | +2,69 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| GOODRX | 4,270 | -0,93 % | GoodRx Holdings one of the most undervalued stocks, Leerink says | ||
| CARMAT | 1,190 | -1,00 % | CARMAT's Aeson Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe | Milestone of 30 heart transplants post Aeson® support, passed Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first... ► Artikel lesen | |
| JOINT CORP | 11,095 | -1,90 % | JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3% | ||
| MIMEDX | 9,270 | +2,21 % | MIMEDX GROUP, INC. - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 94,11 | +1,52 % | Looking Into PROCEPT BioRobotics' Recent Short Interest | ||
| HYPERFINE | 0,900 | 0,00 % | Hyperfine, Inc. Reports Third Quarter 2024 Financial Results | GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| BIOMERICA | 0,310 | -3,16 % | Biomerica secures patents for GI treatments in Europe | ||
| PROGYNY | 14,410 | +3,08 % | Barclays Lowers Progyny (NASDAQ:PGNY) Price Target to $17.00 | ||
| ATRICURE | 36,070 | +0,11 % | Pre-market Movers: ASP Isotopes, NerdWallet, Reddit, AtriCure, Qorvo | OLATHE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green ASP Isotopes Inc. (ASPI) is up over 44% at $8.33.
NerdWallet... ► Artikel lesen |
Das Unternehmen LEXARIA BIOSCIENCE CORP kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXARIA BIOSCIENCE CORP finden Sie auf Wallstreet Online.
